written on 16.05.2014

FDA rejects Novartis AHF drug serelaxin; more efficacy evidence needed


Dr Tim Wright, global head of development at Novartis Pharmaceuticals, said the company planned to continue to expedite its clinical trial program to build the supporting body of evidence for serelaxin per the FDA's advice.

Latest Reports